We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+18.21%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$9.8B
AUM Growth
+$1.86B
Cap. Flow
-$1.4B
Cap. Flow %
-14.24%
Top 10 Hldgs %
73.27%
Holding
123
New
14
Increased
15
Reduced
12
Closed
2

Top Buys

Rank Stock Value
1
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$247M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$188M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$112M
4
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$91.9M
5
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$75.9M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$67.4M
2
XOMA
Xoma
XOMA
+$26.3M
3
AMBI
Ambit Biosciences Corp
AMBI
+$16.8M
4
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$14.3M
5
RPRX
Repros Therapeutics Inc.
RPRX
+$6.64M

Sector Composition

Rank Sector Weight
1 Healthcare 47.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRTX icon
26
Heron Therapeutics
HRTX
$60.4M
$26.2M 0.27%
2,607,784
– –
GILD icon
27
Gilead Sciences
GILD
$181B
$24.1M 0.25%
256,108
– –
CPRX
28
DELISTED
Catalyst Pharmaceutical
CPRX
$19.9M 0.2%
6,715,462
– –
RPRX
29
DELISTED
Repros Therapeutics Inc.
RPRX
$19.9M 0.2%
2,000,000
-778,654
-28% -$6.64M
AGIO icon
30
Agios Pharmaceuticals
AGIO
$1.98B
$18.3M 0.19%
163,393
-6,500
-4% -$580K
INSM icon
31
Insmed
INSM
$27.5B
$17.1M 0.17%
1,107,850
– –
OMER icon
32
Omeros
OMER
$1.39B
$16.1M 0.16%
648,101
-160,674
-20% -$2.93M
SGMO
33
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$14.5M 0.15%
955,332
+90,476
+10% +$1.1M
BLUE
34
DELISTED
bluebird bio
BLUE
$13.8M 0.14%
11,580
– –
NBIX icon
35
Neurocrine Biosciences
NBIX
$15.5B
$12.4M 0.13%
554,590
– –
CLVS
36
DELISTED
Clovis Oncology, Inc.
CLVS
$11.3M 0.12%
+202,630
New +$10.6M
MGNX icon
37
MacroGenics
MGNX
$261M
$10.9M 0.11%
311,891
– –
KYTH
38
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$9.93M 0.1%
286,255
-25,000
-8% -$872K
XNCR icon
39
Xencor
XNCR
$2.07B
$9.49M 0.1%
591,371
+49,008
+9% +$568K
ARWR icon
40
Arrowhead Research
ARWR
$12.3B
$9.08M 0.09%
1,230,802
– –
NGNE icon
41
Neurogene
NGNE
$773M
$9.08M 0.09%
60,518
-75
-0.1% -$10.7K
AERI
42
DELISTED
Aerie Pharmaceuticals
AERI
$8.74M 0.09%
299,356
– –
PRQR icon
43
ProQR Therapeutics
PRQR
$330M
$8.67M 0.09%
400,000
– –
OSIR
44
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$8.16M 0.08%
510,606
– –
VIRX
45
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$8.16M 0.08%
+15,238
New +$6.87M
LJPC
46
DELISTED
La Jolla Pharmaceutical Company
LJPC
$7.78M 0.08%
421,631
– –
ABUS icon
47
Arbutus Biopharma
ABUS
$1.03B
$7.33M 0.07%
484,156
– –
EIGR
48
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$7.32M 0.07%
833
– –
NVAX icon
49
Novavax
NVAX
$1.47B
$7.25M 0.07%
61,168
– –
ACGN
50
DELISTED
Aceragen Inc
ACGN
$7.18M 0.07%
11,984
+66
+0.6% +$26.5K
1
2
3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q4 2014 Portfolio in Review

As of Q4 2014, Julian Baker held 123 positions worth $9.8B, up 23% from $7.94B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Julian Baker withdrew a net $1.4B in Q4 2014, closing 2 positions and reducing 12 holdings. Its most notable exit was Ambit Biosciences Corp, an estimated $16.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 44% a quarter earlier.

Against the trend, Julian Baker opened a new position in Bellicum Pharmaceuticals, Inc. worth $98.7M.

  • Julian Baker's largest Q4 2014 buy was Bellicum Pharmaceuticals, Inc.: 428,373 shares worth $98.7M.
  • Julian Baker added most to AVANIR PHARMACEUTICALS, INC CL A in Q4 2014, an estimated $247M increase.
  • Julian Baker's biggest Q4 2014 reduction was PHARMACYCLICS INC, cutting an estimated $67.4M.
  • Julian Baker fully exited Ambit Biosciences Corp in Q4 2014, selling an estimated $16.8M.
  • Julian Baker's ten largest holdings make up 73% of its $9.8B portfolio in Q4 2014.
  • Julian Baker opened 14 new positions and closed 2 in Q4 2014.
  • Julian Baker's portfolio value rose 23% quarter-over-quarter to $9.8B.

Based on Baker Bros. Advisors's 13F filing for Q4 2014, filed 17 Feb 2015.